Anterocollis: Clinical features and treatment options

Medical Science Monitor

Volumn 14, Issue 9, 2008, Pages

  Papapetropoulos, Spiridon ^a   Tuchman, Alexander ^a   Sengun, Cenk ^a   Russell, Angella ^a   Mitsi, Georgia ^b   Singer, Carlos ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Antecolllis; Anterocollis; Botulinum toxin; Cervical dystonia; Clinical characteristics; Risk factors

Indexed keywords

BACLOFEN; BENZATROPINE; BOTULINUM TOXIN; CLONAZEPAM; NEUROLEPTIC AGENT; TETRABENAZINE; TRIHEXYPHENIDYL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTEROCOLLIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DYSPHAGIA; DYSTONIA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE PAIN; MALE; ONSET AGE; RISK FACTOR; SEX DIFFERENCE; XEROSTOMIA;

AGED; BOTULINUM TOXINS; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; TORTICOLLIS; TREATMENT OUTCOME;

EID: 52249098639     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jankovic J, Leder S, Warner D, Schwartz K: Cervical dystonia: Clinical findings and associated movement disorders. Neurology, 1991; 41: 1088-91
2. Quinn N: Disproportionate antecollis in multiple system atrophy. Lancet, 1989; 1: 844
3. Jorens PG, Eycken MP, Panzel GA, Martin JJ: Antecollis in parkinsonism. Lancet, 1989; 1: 1320-21
4. Kashihara K, Ohno M, Tomita S: Dropped head syndrome in parkinson's disease. Mov Disord, 2006; 21: 1213-16
5. Papapetropoulos S, Baez S, Zitser J et al: Classification, clinical phenotype, treatment outcomes and risk factors. Eur Neurol, 2007; in press
6. Knopman DS, Knapp MJ, Gracon SI, Davis CS: The clinician interview-based impression (cibi): A clinician's global change rating scale in alzheimer's disease. Neurology, 1994; 44: 2315-21
7. Fernandez HH, Friedman JH: Classification and treatment of tardive syndromes. Neurologist, 2003; 9: 16-27
8. Kang UJ, Burke RE, Fahn S: Natural history and treatment of tardive dystonia. Mov Disord, 1986; 1: 193-208
9. Jankovic J: Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord, 2001; 16: 7-12
10. Samii A, Pal PK, Schulzer M et al: Post-traumatic cervical dystonia: A distinct entity? The Canadian journal of neurological sciences, 2000; 27: 55-59
11. Kutvonen O, Dastidar P, Nurmikko T: Pain in spasmodic torticollis. Pain, 1997; 69: 279-86
12. Slawek J, Derejko M, Lass P, Dubaniewicz M: Camptocormia or pisa syndrome in multiple system atrophy. Clin Neurol Neurosurg, 2006; 108: 699-704
13. Fujimoto K: Dropped head in parkinson's disease. J Neurol, 2006; 253(Suppl.7): VII21-26
14. Boesch SM, Wenning GK, Ransmayr G, Poewe W: Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry, 2002; 72: 300-3
15. Velickovic M, Benabou R, Brin MF: Cervical dystonia pathophysiology and treatment options. Drugs, 2001; 61: 1921-43
16. Thant ZS, Tan EK: Emerging therapeutic applications of botulinum toxin. Med Sci Monit, 2003; 9(2): RA40-48
17. Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord, 2007; 22: 192-97
18. Jankovic J, Orman J: Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology, 1988; 38: 391-94